09.16.15
ReWalk Robotics Ltd., a developer and manufacturer of exoskeleton technology, has appointed former Philips Healthcare CEO Deborah DiSanzo to its board of directors.
From 2012 to 2014, DiSanzo was chief executive of Philips Healthcare. Prior to her role as CEO, she was CEO of Patient Care and Clinical Informatics, CEO of Healthcare Informatics and Patient Monitoring and General Manager of Patient Monitoring. Deborah joined Philips in 2001 when Philips acquired Agilent's Healthcare Solutions Group. She received her B.S. from Merrimack College and M.B.A. from Babson College.
"We are very pleased to welcome Deborah DiSanzo to our board and draw upon her expertise as a seasoned medical device executive and leader in our industry as we work to expand our commercialization efforts for the ReWalk exoskeleton and build shareholder value," said Larry Jasinski, CEO of ReWalk.
ReWalk is a wearable robotic exoskeleton that provides powered hip and knee motion to enable individuals with spinal cord injury to stand upright, walk, turn, and climb and descend stairs. It is the only U.S. Food and Drug Administration-cleared exoskeleton for rehabilitation and personal use in the United States.
DiSanzo commented: "I am proud to join ReWalk at this point in its journey, as the company advances its commercialization efforts to transform the lives of many more individuals with lower limb disabilities. I look forward to working with ReWalk management and my accomplished colleagues on the board of directors to expand the reach of ReWalk exoskeletons around the world."
ReWalk has offices in Israel and Marlborough, Mass.
From 2012 to 2014, DiSanzo was chief executive of Philips Healthcare. Prior to her role as CEO, she was CEO of Patient Care and Clinical Informatics, CEO of Healthcare Informatics and Patient Monitoring and General Manager of Patient Monitoring. Deborah joined Philips in 2001 when Philips acquired Agilent's Healthcare Solutions Group. She received her B.S. from Merrimack College and M.B.A. from Babson College.
"We are very pleased to welcome Deborah DiSanzo to our board and draw upon her expertise as a seasoned medical device executive and leader in our industry as we work to expand our commercialization efforts for the ReWalk exoskeleton and build shareholder value," said Larry Jasinski, CEO of ReWalk.
ReWalk is a wearable robotic exoskeleton that provides powered hip and knee motion to enable individuals with spinal cord injury to stand upright, walk, turn, and climb and descend stairs. It is the only U.S. Food and Drug Administration-cleared exoskeleton for rehabilitation and personal use in the United States.
DiSanzo commented: "I am proud to join ReWalk at this point in its journey, as the company advances its commercialization efforts to transform the lives of many more individuals with lower limb disabilities. I look forward to working with ReWalk management and my accomplished colleagues on the board of directors to expand the reach of ReWalk exoskeletons around the world."
ReWalk has offices in Israel and Marlborough, Mass.